We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 72.4%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARCT icon
51
Arcturus Therapeutics
ARCT
$161M
$11.7M 0.1%
255,696
– –
MGNX icon
52
MacroGenics
MGNX
$234M
$11.6M 0.1%
305,043
– –
AGIO icon
53
Agios Pharmaceuticals
AGIO
$2.09B
$11.1M 0.1%
100,000
-49,954
-33% -$5.38M
LJPC
54
DELISTED
La Jolla Pharmaceutical Company
LJPC
$10.1M 0.09%
412,008
– –
LRMR icon
55
Larimar Therapeutics
LRMR
$385M
$9.96M 0.09%
23,973
+16,078
+204% +$6.73M
OSIR
56
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$9.71M 0.09%
499,193
– –
VIRX
57
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$9.63M 0.08%
15,238
– –
RXDX
58
DELISTED
Ignyta, Inc.
RXDX
$8.62M 0.08%
571,000
– –
NGNE icon
59
Neurogene
NGNE
$645M
$8.31M 0.07%
59,868
+485
+0.8% +$73.8K
SAGE
60
DELISTED
Sage Therapeutics
SAGE
$7.67M 0.07%
105,000
+30,000
+40% +$1.93M
LGND icon
61
Ligand Pharmaceuticals
LGND
$5.84B
$7.41M 0.07%
117,638
– –
CNCE
62
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.38M 0.06%
495,908
– –
ARWR icon
63
Arrowhead Research
ARWR
$12.1B
$7.22M 0.06%
1,009,509
-280,678
-22% -$1.93M
KPTI icon
64
Karyopharm Therapeutics
KPTI
$154M
$5.9M 0.05%
14,466
– –
EPZM
65
DELISTED
Epizyme, Inc
EPZM
$5.58M 0.05%
232,481
– –
AMRN
66
Amarin Corp
AMRN
$294M
$5.43M 0.05%
110,286
– –
AFMD
67
DELISTED
Affimed
AFMD
$5.39M 0.05%
40,000
– –
CMRX
68
DELISTED
Chimerix, Inc.
CMRX
$5.32M 0.05%
115,216
– –
AERI
69
DELISTED
Aerie Pharmaceuticals
AERI
$5.28M 0.05%
299,356
– –
VNDA icon
70
Vanda Pharmaceuticals
VNDA
$302M
$5.2M 0.05%
409,881
-1,340,349
-77% -$14.5M
MCRB icon
71
Seres Therapeutics
MCRB
$46M
$5.19M 0.05%
+6,250
New +$5.45M
CYTR
72
DELISTED
CytRx Corp
CYTR
$4.91M 0.04%
219,998
– –
ASMB icon
73
Assembly Biosciences
ASMB
$495M
$4.82M 0.04%
20,833
– –
RCPT
74
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$4.54M 0.04%
23,900
– –
JUNO
75
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.27M 0.04%
80,000
-20,000
-20% -$1.06M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Baker Bros. Advisors held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 40% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Baker Bros. Advisors's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Baker Bros. Advisors's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Baker Bros. Advisors fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Baker Bros. Advisors opened 10 new positions and closed 12 in Q2 2015.
  • Baker Bros. Advisors's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.